

# ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

**Manchester, United Kingdom**  
**7-9 March 2018**

---

## CO-CHAIRS:

Fiona Blackhall, United Kingdom  
Raffaele Califano, United Kingdom

## SPEAKERS:

Mo Al Aloul, United Kingdom  
Neil Bayman, United Kingdom  
Haval Balata, United Kingdom  
Benjamin Besse, France  
Richard Booton, United Kingdom  
Simon Ekman, Sweden  
Corinne Faivre-Finn, United Kingdom  
Martin Früh, Switzerland  
Marina Garassino, Italy  
Pilar Garrido, Spain  
Gerry Hanna, United Kingdom  
Keith Kerr, United Kingdom  
Rohit Kochhar, United Kingdom

Jaroslaw Kuzdzal, Poland  
Cecile Le Péchoux, France  
Catherine McBain, United Kingdom  
Silvia Novello, Italy  
Ugo Pastorino, Italy  
Giorgio Scagliotti, Italy  
Suresh Senan, Netherlands  
Hamid Sheikh, United Kingdom  
Tora S. Solheim, Norway  
Yvonne Summers, United Kingdom  
Paul Taylor, United Kingdom  
Paul E. Van Schil, Belgium  
David Woolf, United Kingdom

---

## LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

---

## ACCREDITATION

The programme of this event has been accredited with **15 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certain medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from:



## Wednesday, 7 March 2018

<b>08:15-09:15</b> 60'	<b>Registration</b>	
<b>09:15-10:55</b> 100'	<b>SESSION 1</b> <b>Screening and diagnostics for lung cancer</b>	<b>Chairs: Raffaele Califano, UK and Keith Kerr, UK</b>
40'	Lung cancer screening: Pro and Contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith Kerr, UK
<b>10:55-11:15</b>	<b>Coffee break</b>	
<b>11:15-12:15</b> 60'	<b>SESSION 1</b> <b>Screening and diagnostics for lung cancer - cont.</b>	<b>Chairs: Fiona Blackhall, UK and Raffaele Califano, UK</b>
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
<b>12:15-13:05</b>	<b>Lunch</b>	
<b>13:05-14:05</b> 60'	<b>SESSION 2</b> <b>Radical treatment of early stage NSCLC</b>	<b>Chairs: Cecile Le Pechoux, FR and Ugo Pastorino, IT</b>
30'	Surgery for early stage NSCLC	Ugo Pastorino, IT
30'	Adjuvant radiotherapy for completely resected early stage NSCLC	Cecile Le Pechoux, FR
<b>14:05-14:25</b>	<b>Coffee Break</b>	
<b>14:25-15:25</b> 60'	<b>SESSION 2</b> <b>Radical treatment of early stage NSCLC – cont.</b>	<b>Chairs: Cecile Le Pechoux, FR and Ugo Pastorino, IT</b>
30'	Adjuvant chemotherapy for resected early stage NSCLC	Paul Taylor, UK
<b>15:25-15:35</b> 10'	<b>Close of day 1</b>	<b>Chairmen</b>

## Thursday, 8 March 2018

<b>09:05-11:05</b> 120'	<b>SESSION 3</b> <b>Advanced NSCLC</b>	<b>Chairs: Silvia Novello, IT and Benjamin Besse, FR</b>
30'	Stereotactic ablative RT for early stages NSCLC	Suresh Senan, NL
30'	1 <sup>st</sup> line chemotherapy for advanced NSCLC	Benjamin Besse, FR
30'	2 <sup>nd</sup> line treatment for advanced NSCLC	Silvia Novello, IT
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
<b>11:05-11:25</b>	<b>Coffee break</b>	
<b>11:25-12:45</b> 80'	<b>SESSION 3</b> <b>Advanced NSCLC - cont.</b>	<b>Chairs: Yvonne Summers, UK and Marina Garassino, IT</b>
20'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK
30'	Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Immune checkpoint blockade for NSCLC	Marina Garassino, IT

12:45-13:35	Lunch	
13:35-15:05 90'	<b>SESSION 4</b> Palliative treatment of lung cancer and mesothelioma	<b>Chairs: Catherine McBain, UK and Giorgio Scagliotti, IT</b>
30'	Systemic treatment of mesothelioma	Giorgio Scagliotti, IT
30'	Treatment of oligometastatic NSCLC	Jaroslav Kuzdzal, PL
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Catherine McBain, UK
15:05-15:25	Coffee break	
15:25-16:25 60'	<b>SESSION 4</b> Palliative treatment of lung cancer and mesothelioma - cont.	<b>Chairs: Raffaele Califano, UK and Tora S. Solheim, NOR</b>
30'	Supportive and palliative care in lung cancer	Tora S. Solheim, NO
30'	Intra-luminal radiotherapy	Hamid Sheikh, UK
16:25-16:35 10'	Close of day 2	Chairmen
19:00	Welcome drink	
19:30	Dinner	

## Friday, 9 March 2018

09:05-10:35 90'	<b>SESSION 5</b> Locally advanced NSCLC	<b>Chairs: Paul E. Van Schil, BE and Corinne Faivre-Finn, UK</b>
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Gerry Hanna, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:35-11:00	Coffee break	
11:00-12:00 60'	<b>SESSION 5</b> Locally advanced NSCLC - cont.	<b>Chairs: P Van Schil, BE and Corinne Faivre-Finn, UK</b>
3x20'	3 x Participant clinical case discussion	Faculty

Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion

12:00-12:50	Lunch	
12:50-14:20 90'	<b>SESSION 6</b> SCLC	<b>Chairs: Pilar Garrido, ES and Corinne Faivre-Finn, UK</b>
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	Treatment of extensive stage SCLC	Martin Früh, CH
30'	Targeted agents in SCLC	Pilar Garrido, ES
14:20-14:40	Coffee break	
14:40-15:40 60'	<b>SESSION 6</b> SCLC - cont.	<b>Chair: Corinne Faivre-Finn, UK and Raffaele Califano, UK</b>
30'	Prophylactic cranial irradiation and role of thoracic RT for	Neil Bayman, UK

	extensive stage SCLC	
30'	Versatility of circulating tumour cells in SCLC – biomarkers, biology, mouse models and drug development	<b>Fiona Blackhall, UK</b>
30'	Treatment of ALK positive advanced NSCLC	Fiona Blackhall, UK
<b>15:40-15:50 10'</b>	<b>Conclusion and farewell</b>	<b>Raffaele Califano, UK</b>